The Princess Margaret University Health Network (PM-UHN) Tumor Immunotherapy Program (TIP) and melanoma referral databases were used to identify patients with uveal melanoma who received anti-PD1/L1-based ICI (either alone or in combination with anti-CTLA4) as palliative treatment for advanced disease. This evidence concerns the gene CTLA4 and uveal melanoma.